Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Publications

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Neurology and Therapy

Author(s)

Laura Obici, Senda Ajroud-Driss, Kon-Ping Lin, et al

Transthyretin Amyloidosis (ATTR)

Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy

Expert Opinion on Pharmacotherapy

Author(s)

Madeline Merkel, David Danese, Chongshu Chen, et al

Transthyretin Amyloidosis (ATTR)

Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study

European Journal of Heart Failure

Author(s)

Hannah Rosenblum, Jan Griffin, Masatoshi Minamisawa, et al

Transthyretin Amyloidosis (ATTR)

Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial

Amyloid

Author(s)

Dianna Quan, Laura Obici, John Ber, et al

Transthyretin Amyloidosis (ATTR)

Gene Silencing Therapeutics in Cardiology: A Review Article

International Journal of Cardiovascular Sciences

Author(s)

Patrick Jay, Martin Maier, Laura Saltonstall, et al